King Pharmaceuticals KG Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | ||
|---|---|---|---|---|---|
| Leverage | |||||
| Debt-to-equity | 1.5×— | —— | —— | —— | |
| Debt-to-assets | 0.2×— | —— | —— | —— | |
| Per Share | |||||
| Book value per share | $15.66-30.0% | $22.38+20.5% | $18.57-42.6% | $32.38+2,006% | |
| Valuation | |||||
| Market capitalization | $70.42M-67.6% | —— | —— | —— | |
| Enterprise value | $184.93M-50.0% | —— | —— | —— | |
| Price / sales | 1.6×-24.3× | —— | —— | —— | |
| Price / book | 0.7×-1.0× | —— | —— | —— | |
| EV / sales | 4.5×-41.9× | —— | —— | —— |
Questions, answered.
- Where do King Pharmaceuticals's ratios come from?
- Every ratio is computed from King Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
